Medical Devices and Diagnostics: Raising PE Capital in India

Medical devices and diagnostics represent two of the most rapidly growing segments within India's life sciences sector. Both are attracting sustained PE investment driven by the structural underpenetration of quality healthcare infrastructure, growing insurance coverage, and increasing clinical awareness among Indian patients and physicians. For founders in these businesses, understanding what PE investors look for, how valuations are constructed, and what deal structures are available is essential preparation for a successful capital raise.

Key Takeaways

• Medical device companies with regulatory approvals, proprietary technology, and export revenues attract premium PE valuations from both India-focused and global healthcare funds.
• Diagnostic chains with multi-city presence, technology-enabled operations, and growing payor mix attract EBITDA multiples of 14x to 20x in PE transactions.
• Regulatory compliance, IP ownership clarity, and management depth are the three most common gaps that delay or reduce valuations in medtech and diagnostics PE deals.

‍

Why PE Is Targeting Medical Devices and Diagnostics in India

India's medical device market is growing rapidly, driven by increasing healthcare access, growing insurance penetration, and rising demand for quality diagnostic and therapeutic equipment. The market, estimated at USD 12billion, is projected to grow at 15% annually and reach USD 50 billion by 2030. Despite this growth, India imports approximately 70% of its medical device requirements, creating a massive import substitution opportunity for domestic manufacturers that PE investors see as a long-term structural advantage.

Government policy is actively supporting domestic medical device manufacturing. The Production Linked Incentive scheme for medical devices, the establishment of dedicated medical device manufacturing parks in Uttar Pradesh, Tamil Nadu, Madhya Pradesh, and Himachal Pradesh, along with the Andhra Pradesh MedTech Zone (AMTZ) facility in Telangana, and the updated Medical Devices Rules 2017 have created a more supportive regulatory environment for both manufacturing and investment. These policy tailwinds are making PE investors more confident about the growth trajectory of well-positioned Indian medical device companies.

The diagnostics sector presents an equally compelling investment case. India has approximately 100,000 diagnostic laboratories, but the vast majority are small, unorganised single-location businesses. The organised diagnostics market, led by companies such as Dr Lal PathLabs, Metropolis, and SRL, accounts for only a small fraction of total diagnostic spending. This fragmentation creates a massive opportunity for well-capitalised diagnostics businesses to consolidate the market through organic expansion and strategic acquisitions.

For both medical devices and diagnostics, the COVID-19 pandemic was a significant inflection point. It demonstrated the critical importance of domestic diagnostic infrastructure, accelerated the adoption of point-of-care testing, expanded the customer base for homecare medical devices, and validated the scalability of technology-enabled diagnostics platforms. PE investors drew clear lessons about the sector's resilience and growth potential. Our broader analysis of healthcare PE in India is covered in the private equity india sector guide, while the adjacent life sciences opportunity is detailed in our guide on PE funding for life sciences companies.

Key Metrics PE Investors Use to Evaluate Medical Device Companies

Medical device company evaluations focus on a combination of financial performance metrics and strategic positioning factors. On the financial side, gross margin is the primary indicator of product value and manufacturing efficiency. Medical device companies targeting PE investment typically need gross margins above 40%, with proprietary technology or regulatory-approved devices in high-demand clinical applications commanding margins of 50% to 70%. EBITDA margins above 15% are the baseline expectation for profitable device companies.

Revenue quality is examined in detail. PE investors strongly prefer recurring revenue from consumables, service contracts, and reagent-based business models over one-time capital equipment sales. A device company where 60% or more of revenues are recurring is valued significantly more highly than one dependent on project-based equipment sales. The MedTech recurring revenue model mirrors the razor-and-blade principle: the installed base of capital equipment generates a long-term stream of consumable and service revenue that compounds over time.

Product pipeline and regulatory filing activity are strategic metrics that PE investors use to assess the future growth potential beyond current revenues. A company with multiple products in various stages of domestic and international regulatory review is valued more highly than one whose current product range is mature and facing generic competition. The regulatory approval timeline for Indian medical device registrations has shortened under the updated rules, making pipeline depth a more bankable asset than it was five years ago.

Export revenue proportion is a significant valuation driver. Medical device companies generating revenues from the US, European Union, or other regulated markets have validated their quality standards through the most rigorous regulatory frameworks in the world. This validation gives PE investors confidence in the company's manufacturing quality, regulatory compliance capability, and competitive positioning. Export-oriented device companies typically command a valuation premium of 20% to 30% over purely domestic businesses with comparable financial metrics.

Valuation Approaches for Diagnostic Chains

Diagnostic chain valuations use different methodologies from medical device companies, reflecting the service-based nature of the business model. EBITDA multiples are the primary valuation tool for established diagnostic chains with stable, recurring revenues from pathology, radiology, and other diagnostic services. Well-run multi-city diagnostic chains in India have transacted at EBITDA multiples of 14x to 20x, with premium businesses commanding above this range. The comparable listed businesses such as Dr Lal PathLabs and Metropolis provide valuation benchmarks that PE investors use as reference points.

Revenue per lab is a key operating metric used in diagnostic chain valuations alongside EBITDA multiples. PE investors will benchmark the revenue productivity of each location in the chain against sector averages and against the target chain's own best-performing locations. Large gaps between the best and worst-performing locations may signal untapped improvement potential, a positive signal for a PE fund building a value creation thesis on operational improvement.

Collection point density and the ratio of collection centres to processing laboratories is an important scalability metric. Diagnostic chains that have built a network of collection points feeding into centralised processing laboratories have significantly lower capital requirements for geographic expansion than chains that build full laboratories at each location. PE investors view high collection-point-to-lab ratios as evidence of a capital-efficient expansion model.

Technology adoption is increasingly factored into diagnostic chain valuations. Chains that have invested in laboratory information management systems, automated specimen handling, digital reporting, and home collection platforms are valued more highly than manual or partially automated operations. Technology infrastructure reduces cost, improves throughput, and enables the kind of multi-location standardisation that makes a diagnostic chain scalable with PE capital.

Deal Structures and Investment Sizes

PE investments in medical device companies typically range from Rs 50 crore for early-stage growth equity in smaller specialised device businesses to Rs 500 crore or more for larger manufacturers targeting international markets. The deal structure for most growth equity transactions is a primary issuance of new shares at a negotiated valuation, with the proceeds used to fund capacity expansion, regulatory filing programmes, or export market development. Control transactions are less common but occur in buyout scenarios involving founder succession or family business restructuring.

Diagnostic chain PE deals range in size from Rs 50 crore for regional multi-location chains to Rs 500 crore or more for established national platforms. The deal structure typically involves a combination of primary capital for expansion and a secondary component where the founders realise partial liquidity. Earn-out provisions tied to revenue or EBITDA targets over the first two to three years post-investment are sometimes used to bridge valuation gaps between founder expectations and investor conservatism.

Structured instruments including convertible debentures and redeemable preference shares are used in both device and diagnostics transactions, particularly when there is valuation uncertainty tied to near-term catalysts such as regulatory approvals, new product launches, or major customer contract closings. These instruments provide PE investors with downside protection while preserving the ability to participate fully in equity upside once the value-creating event occurs.

Regulatory and IP Considerations

Medical device regulatory compliance in India is governed by the Medical Devices Rules 2017 and overseen by the Central Drugs Standard Control Organisation. PE investors will conduct detailed due diligence on the registration status of all products in the portfolio, the audit history of manufacturing facilities, and any pending regulatory actions or product recalls. For companies targeting export markets, the regulatory status of US FDA, CE marking, and other relevant country-specific approvals is the primary regulatory due diligence focus.

Quality management system certification under ISO 13485 is the baseline requirement for medical device companies seeking PE investment. This standard establishes the requirements for a quality management system specific to medical devices and is a prerequisite for CE marking, US FDA registration, and recognition under many international procurement frameworks. Companies without current ISO 13485 certification should prioritise obtaining it as part of their PE preparation.

IP ownership and freedom to operate are carefully examined in medical device PE due diligence, particularly for companies manufacturing proprietary devices or using specialised manufacturing processes. PE investors will engage specialist IP counsel to conduct a freedom-to-operate analysis confirming that the company's products do not infringe third-party patents. Any IP assets, including patents, design registrations, and proprietary software, should be clearly owned by the company entity rather than by individuals or related parties.

Preparing Your Business for PE Investment

Medical device and diagnostics companies preparing for PE investment should focus on three preparation priorities: financial transparency, regulatory readiness, and management team strengthening. Financial preparation requires three years of audited financial statements with revenue clearly segmented by product or service category, geography, and customer. Any related-party transactions should be restructured on arm's length terms and clearly disclosed. A five-year financial model with bottom-up revenue projections and scenario analysis is essential for investor presentations.

Regulatory readiness means ensuring that all product registrations, manufacturing facility certifications, and quality management systems are current, documented, and accessible for due diligence review. Any pending regulatory actions or outstanding observations from inspection visits must be addressed and resolved before investor engagement begins. For device companies targeting export markets, engaging a regulatory consultant to conduct a pre-audit of facilities against the relevant international standards is a high-return preparatory investment.

Management team strengthening is essential. PE investors want to see a professional management structure that can operate independently of the founding promoter. For medical device companies, this means a qualified Quality Assurance and Regulatory Affairs leadership team, an experienced CFO, and a commercial leadership team capable of managing both domestic and export sales. For diagnostic chains, the equivalent requirement is professional laboratory management, a CFO, and a regional operations management team capable of overseeing multiple locations.

Building the PE Investment Narrative

The investment narrative for a medical device or diagnostics PE raise must clearly articulate the market opportunity, the business's competitive positioning, the specific use of PE capital, and the expected outcome. For device companies, the narrative typically centres on import substitution, export market penetration, or the launch of a product with clinical differentiation. For diagnostic chains, the narrative usually centres on geographic expansion into underserved markets, acquisition-led consolidation, or technology-enabled margin improvement. The narrative should be grounded in specific, verifiable data rather than sector-level generalisations.

How FinLead Helps Medical Device and Diagnostic Companies Raise PE Capital

FinLead's private equity advisory team works with medical device manufacturers and diagnostic chain businesses at every stage of the PE journey. Our team understands the specific investor criteria, due diligence dimensions, and deal structuring approaches that medtech and diagnostics transactions require. We bring established relationships with the PE funds most active in these segments and know how to position businesses to earn their conviction.

Our engagement begins with a PE-readiness assessment that evaluates your financial profile, regulatory status, IP position, management team, and competitive positioning against the criteria that PE investors apply. We work with you to address any gaps before investor engagement begins and prepare a compelling investor package that communicates your business's value proposition clearly and credibly.

Contact FinLead today to begin the conversation about PE funding for your medical device or diagnostics business. Our team will assess your PE potential and outline a clear path to a successful capital raise.

‍

Frequently Asked Questions

What types of medical device companies attract PE investment in India?

Medical device companies with proprietary technology, regulatory approvals from India and international markets, recurring revenue from consumables or service contracts, and strong gross margins above 40% attract the highest PE interest. Export-oriented businesses with US FDA or CE-marked products command premium valuations.

What EBITDA multiples do diagnostic chains receive in PE transactions?

Established multi-city diagnostic chains in India transact at EBITDA multiples of 14x to 20x in PE deals. Premium businesses with strong national brands, high technology adoption, and consistent margin expansion have achieved multiples above this range. High-growth early-stage chains may be valued on revenue multiples.

Is ISO 13485 certification required for medical device PE investment?

ISO 13485 quality management system certification is effectively a baseline requirement for medical device companies seeking PE investment in India. It is a prerequisite for CE marking and US FDA registration and provides investors with confidence in the quality management infrastructure of the manufacturing operations.

How large are typical PE investments in Indian medical device companies?

PE investments in Indian medical device companies range from Rs 50 crore for early-stage growth equity in specialised device businesses to Rs 500 crore or more for established manufacturers with international revenues. The investment size depends on the stage of the business, the growth plan, and the fund mandate.

What is the recurring revenue model for medical device companies?

The medical device recurring revenue model operates like a razor-and-blade system: capital equipment is placed with clinical customers at low or no margin, generating a long-term stream of high-margin consumable and reagent revenue. This model is strongly preferred by PE investors because of its revenue predictability and compounding nature.

How do PE investors assess competition in diagnostic chain markets?

PE investors assess competitive dynamics for diagnostic chains by mapping existing organised and unorganised diagnostic capacity in each geographic market, identifying the chain's market share and brand recognition, and evaluating barriers to competitive entry such as accreditations, equipment quality, and physician referral relationships.

What regulatory approvals matter most for diagnostic chain PE deals?

NABL accreditation for laboratories, NABH accreditation for any embedded clinical services, state clinical establishment registration, and biomedical waste management authorisations are the primary regulatory requirements for diagnostic chain PE due diligence in India.

How can FinLead help a medical device or diagnostics company prepare for PE?

FinLead conducts a comprehensive PE-readiness assessment, prepares investor materials including the CIM and financial model, targets the most relevant PE funds for your segment, and manages the fundraising process from initial investor engagement through to financial close. Our team brings deep healthcare sector knowledge and established fund relationships.

‍